CN108276487A - 一种可促进成骨并抑制破骨的活性多肽及其应用 - Google Patents
一种可促进成骨并抑制破骨的活性多肽及其应用 Download PDFInfo
- Publication number
- CN108276487A CN108276487A CN201711459182.9A CN201711459182A CN108276487A CN 108276487 A CN108276487 A CN 108276487A CN 201711459182 A CN201711459182 A CN 201711459182A CN 108276487 A CN108276487 A CN 108276487A
- Authority
- CN
- China
- Prior art keywords
- polypeptide
- pthrp
- calcium
- slow
- bone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 56
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 49
- 230000001599 osteoclastic effect Effects 0.000 title claims abstract description 16
- 239000000463 material Substances 0.000 claims abstract description 57
- 229920001184 polypeptide Polymers 0.000 claims abstract description 43
- 230000000694 effects Effects 0.000 claims abstract description 31
- 210000000963 osteoblast Anatomy 0.000 claims abstract description 21
- ZQBZAOZWBKABNC-UHFFFAOYSA-N [P].[Ca] Chemical compound [P].[Ca] ZQBZAOZWBKABNC-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000011248 coating agent Substances 0.000 claims abstract description 12
- 238000000576 coating method Methods 0.000 claims abstract description 12
- 230000001737 promoting effect Effects 0.000 claims abstract description 8
- 210000004899 c-terminal region Anatomy 0.000 claims abstract description 7
- 230000026731 phosphorylation Effects 0.000 claims abstract description 7
- 238000006366 phosphorylation reaction Methods 0.000 claims abstract description 7
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims abstract description 6
- 235000003704 aspartic acid Nutrition 0.000 claims abstract description 6
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims abstract description 6
- 230000003252 repetitive effect Effects 0.000 claims abstract description 6
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims abstract description 5
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims abstract description 4
- 235000013922 glutamic acid Nutrition 0.000 claims abstract description 4
- 239000004220 glutamic acid Substances 0.000 claims abstract description 4
- 210000000988 bone and bone Anatomy 0.000 claims description 31
- 210000004027 cell Anatomy 0.000 claims description 22
- 239000002131 composite material Substances 0.000 claims description 18
- MWKXCSMICWVRGW-UHFFFAOYSA-N calcium;phosphane Chemical compound P.[Ca] MWKXCSMICWVRGW-UHFFFAOYSA-N 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 9
- 238000005242 forging Methods 0.000 claims description 7
- 229920001661 Chitosan Polymers 0.000 claims description 6
- 229910052588 hydroxylapatite Inorganic materials 0.000 claims description 6
- 239000005313 bioactive glass Substances 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 210000002449 bone cell Anatomy 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 238000004108 freeze drying Methods 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 108090000445 Parathyroid hormone Proteins 0.000 abstract description 26
- 210000002997 osteoclast Anatomy 0.000 abstract description 23
- 208000001132 Osteoporosis Diseases 0.000 abstract description 14
- 239000007924 injection Substances 0.000 abstract description 7
- 238000002347 injection Methods 0.000 abstract description 7
- 101001135770 Homo sapiens Parathyroid hormone Proteins 0.000 abstract description 5
- 101001135995 Homo sapiens Probable peptidyl-tRNA hydrolase Proteins 0.000 abstract description 5
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 abstract description 5
- 229910000389 calcium phosphate Inorganic materials 0.000 abstract description 5
- 239000001506 calcium phosphate Substances 0.000 abstract description 5
- 235000011010 calcium phosphates Nutrition 0.000 abstract description 5
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 abstract description 5
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 3
- 238000005336 cracking Methods 0.000 abstract description 3
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 abstract description 2
- 101000762366 Homo sapiens Bone morphogenetic protein 2 Proteins 0.000 abstract description 2
- 238000001647 drug administration Methods 0.000 abstract description 2
- 102100036893 Parathyroid hormone Human genes 0.000 abstract 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 108010005636 polypeptide C Proteins 0.000 abstract 1
- 108010082006 PTH-related peptide-1 PTHrP-1 Proteins 0.000 description 55
- 102000003982 Parathyroid hormone Human genes 0.000 description 25
- 239000000199 parathyroid hormone Substances 0.000 description 24
- 229960001319 parathyroid hormone Drugs 0.000 description 24
- 230000007547 defect Effects 0.000 description 21
- 150000001875 compounds Chemical class 0.000 description 15
- 239000011521 glass Substances 0.000 description 14
- 238000000034 method Methods 0.000 description 14
- 241000700159 Rattus Species 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 230000008569 process Effects 0.000 description 11
- 241000283973 Oryctolagus cuniculus Species 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 230000008439 repair process Effects 0.000 description 6
- 102100031475 Osteocalcin Human genes 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000002188 osteogenic effect Effects 0.000 description 5
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 238000011068 loading method Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 208000010392 Bone Fractures Diseases 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 108010049264 Teriparatide Proteins 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 230000004097 bone metabolism Effects 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 210000003625 skull Anatomy 0.000 description 3
- OGBMKVWORPGQRR-UMXFMPSGSA-N teriparatide Chemical compound C([C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CNC=N1 OGBMKVWORPGQRR-UMXFMPSGSA-N 0.000 description 3
- 229960005460 teriparatide Drugs 0.000 description 3
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical group CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- ULBHWNVWSCJLCO-NHCYSSNCSA-N Arg-Val-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCN=C(N)N ULBHWNVWSCJLCO-NHCYSSNCSA-N 0.000 description 2
- WIDVAWAQBRAKTI-YUMQZZPRSA-N Asn-Leu-Gly Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O WIDVAWAQBRAKTI-YUMQZZPRSA-N 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 206010017076 Fracture Diseases 0.000 description 2
- IXFVOPOHSRKJNG-LAEOZQHASA-N Gln-Asp-Val Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O IXFVOPOHSRKJNG-LAEOZQHASA-N 0.000 description 2
- WVYJNPCWJYBHJG-YVNDNENWSA-N Glu-Ile-Gln Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(O)=O WVYJNPCWJYBHJG-YVNDNENWSA-N 0.000 description 2
- POMXSEDNUXYPGK-IHRRRGAJSA-N Leu-Met-His Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N POMXSEDNUXYPGK-IHRRRGAJSA-N 0.000 description 2
- OWRUUFUVXFREBD-KKUMJFAQSA-N Lys-His-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(O)=O OWRUUFUVXFREBD-KKUMJFAQSA-N 0.000 description 2
- HVAUKHLDSDDROB-KKUMJFAQSA-N Lys-Lys-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O HVAUKHLDSDDROB-KKUMJFAQSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- NIOYDASGXWLHEZ-CIUDSAMLSA-N Ser-Met-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(O)=O NIOYDASGXWLHEZ-CIUDSAMLSA-N 0.000 description 2
- JGUWRQWULDWNCM-FXQIFTODSA-N Ser-Val-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O JGUWRQWULDWNCM-FXQIFTODSA-N 0.000 description 2
- AIISTODACBDQLW-WDSOQIARSA-N Trp-Leu-Arg Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)=CNC2=C1 AIISTODACBDQLW-WDSOQIARSA-N 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 238000011047 acute toxicity test Methods 0.000 description 2
- 108010050025 alpha-glutamyltryptophan Proteins 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 108010062796 arginyllysine Proteins 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000037182 bone density Effects 0.000 description 2
- 238000003501 co-culture Methods 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000003195 fascia Anatomy 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 102000058004 human PTH Human genes 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 239000002085 irritant Substances 0.000 description 2
- 231100000021 irritant Toxicity 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000011587 new zealand white rabbit Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000004072 osteoblast differentiation Effects 0.000 description 2
- 210000004409 osteocyte Anatomy 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 210000000623 ulna Anatomy 0.000 description 2
- 238000005491 wire drawing Methods 0.000 description 2
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 1
- LSJQOMAZIKQMTJ-SRVKXCTJSA-N Asn-Phe-Asp Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(O)=O)C(O)=O LSJQOMAZIKQMTJ-SRVKXCTJSA-N 0.000 description 1
- RAUPFUCUDBQYHE-AVGNSLFASA-N Asn-Phe-Glu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O RAUPFUCUDBQYHE-AVGNSLFASA-N 0.000 description 1
- 241000432824 Asparagus densiflorus Species 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 235000019738 Limestone Nutrition 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 230000005725 N terminal phosphorylation Effects 0.000 description 1
- 208000001164 Osteoporotic Fractures Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 229920000153 Povidone-iodine Polymers 0.000 description 1
- 206010039984 Senile osteoporosis Diseases 0.000 description 1
- 241000238370 Sepia Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229910052586 apatite Inorganic materials 0.000 description 1
- 108010040443 aspartyl-aspartic acid Proteins 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 108010055341 glutamyl-glutamic acid Proteins 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 239000006028 limestone Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000001009 osteoporotic effect Effects 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- VSIIXMUUUJUKCM-UHFFFAOYSA-D pentacalcium;fluoride;triphosphate Chemical compound [F-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O VSIIXMUUUJUKCM-UHFFFAOYSA-D 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003003 phosphines Chemical class 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 229960001621 povidone-iodine Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000000197 pyrolysis Methods 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/635—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
- A61L27/10—Ceramics or glasses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
- A61L27/12—Phosphorus-containing materials, e.g. apatite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/20—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
- A61L27/3608—Bone, e.g. demineralised bone matrix [DBM], bone powder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3641—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the site of application in the body
- A61L27/3645—Connective tissue
- A61L27/365—Bones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Zoology (AREA)
- Botany (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Ceramic Engineering (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明公开了一种可促进成骨并抑制破骨的活性多肽及其应用。是在PTH1‑34的基础上将N端丝氨酸磷酸化，且在C端引入三个重复序列的谷氨酸或天冬氨酸，所述多肽序列为SEQ ID NO:1或SEQ ID NO:2所示；其具有类似BMP2的骨诱导活性，及类似甲状旁腺素PTH抑制破骨细胞的作用。该多肽C端重复序列结合于钙磷材料或表面钙磷涂层材料表面上，避免多肽的无规卷曲，不需要有机试剂的参入，有效地保护多肽的活性，并通过肽键的裂解实现缓慢控制释放，可避免PTH1‑34长期间断注射给药，减轻患者的注射痛，且达到促进成骨细胞、抑制骨质疏松的效果。本发明改变了以往PTH1‑34不能局部给药的观点。
Description
技术领域
本发明涉及骨生物材料与组织工程领域，具体涉及一种可促进成骨并抑制破骨的活性多肽及其应用。
背景技术
现有资料显示，全世界约2亿人患有骨质疏松症，其发病率在慢性疾病中目前已上升至第7位。在我国，60岁以上的骨质疏松症患者已突破8000万，而老年人骨质疏松性骨折的发生率也已达到6.3％-24.4％。骨质疏松性骨折愈合较慢，愈合过程中发生并发症的风险高，同时骨质疏松性骨折的致残率和致死率较高，严重影响患者生活质量，加重卫生系统负担。世界卫生组织(WHO)已将骨质疏松症列为影响老年人身体健康的三大疾病之一。
目前市场上骨质疏松的临床治疗用药以抑制骨吸收的药物为主，如雌激素、双膦酸盐类和降钙素，而其他一些药物则是骨形成促进剂，如氟化物、甲状旁腺激素(PTH)。PTH类药物是目前最有前途的骨形成促进剂，将开发用于原发性骨质疏松症的防治。大规模临床试验表明，甲状旁腺激素(PTH)能够刺激骨形成，明显提高(每年7％到10％)骨密度，组织形态测定研究表明，PTH能够改善骨质疏松中的微结构，并能逆转以前曾经认为不能逆转的骨退化过程。
人体天然PTH含有84个氨基酸，是骨骼、肾脏钙和磷酸盐代谢的主要调节激素，其生理作用包括调节骨代谢、肾小管对钙和磷酸盐的再吸收和肠内钙吸收，小剂量PTH有明显的成骨作用。然而，内源性PTH水平过高对皮质骨和松质骨的成骨作用有不同的影响，如甲状旁腺机能亢进者仅出现整体骨密度(BMD)降低，而松质骨BMD则无明显改变。PTH的N端与C端在骨代谢中发挥的作用不尽相同，N端主要与经典PTH-I型受体结合，影响成骨作用；而C端则通过与另一类受体结合，发挥其他生物学作用，甚至促进骨细胞凋亡。重组人甲状旁腺激素(rhPTH 1-34)特立帕肽(SVSEI-QLMHN-LGKHL-NSMER-VEWLR–KKLQD-VHNF)正是基于上述机制所研发的人PTH类似物，该产品具有与天然PTHN端34个氨基酸序列完全相同的结构，其生物学作用亦是通过与特异性高亲和性PTH-I受体结合介导的。与天然PTH相比，它对骨和肾脏具有相同的生理作用，但克服了C端对骨代谢的不利影响。特立帕肽是目前唯一获美国FDA批准的骨形成促进药物，它不仅可以增加骨量、抑制骨吸收进而逆转骨质疏松，而且可能促进骨折愈合，被认为是治疗严重骨质疏松症的"突破性"进展，但是其存在的问题是价格昂贵，只能注射给药，可引发高钙血症，甚至骨肉瘤风险，而且不能长期使用(2年)。为此，针对骨质疏松性骨折患者骨形成/愈合能力减弱，更需要研发出一种既能促进骨形成、逆转骨质疏松，又能促进骨折愈合和骨缺损修复的新型药物。
重组人甲状旁腺激素(rhPTH 1-34)特立帕肽的生物学活性尚不够稳定,其主要原因是由于该多肽序列较长(含34个氨基酸)，且存在一定的柔曲性，可能发生卷曲，空间结构仍不太稳定，因而与受体结合的优势构象不突出，影响到与受体结合的选择性及活性强度。因此迫切需要进一步优化，筛选出稳定其空间结构，以充分体现小分子活性药物的理想优势。同时，这种PTH活性多肽需要通过适当载体材料缓慢间断控制释放，才能最大程度发挥其骨诱导活性与逆转骨质疏松的能力。
发明内容
为解决以上问题，本发明提供了一种可促进成骨并抑制破骨的活性多肽，该多肽在PTH1-34的基础上将N端丝氨酸磷酸化，同时在C端引入三个重复序列的天冬氨酸(D)或谷氨酸(E)，所得到的多肽既具有类似BMP2的骨诱导活性，又具有类似甲状旁腺素PTH抑制破骨细胞的作用。将所述多肽与钙磷材料复合后，通过肽键的裂解实现缓慢控制释放。
本发明采用的技术方案如下：
本发明第一方面，提供一种可促进成骨并抑制破骨的活性多肽PTHrP-1或PTHrP-2，该多肽是在PTH1-34的基础上将N端丝氨酸磷酸化，同时在C端引入三个重复序列的天冬氨酸(D)或谷氨酸(E)，其氨基酸序列如SEQ ID NO:1或SEQ ID NO:2所示。
本发明第二方面，提供一种缓释复合材料，由上述可促进成骨细胞活性同时抑制破骨细胞活性的多肽PTHrP-1或PTHrP-2搭载钙磷支架材料或钙磷涂层支架材料得到。
优选地，所述复合材料中钙磷支架材料或钙磷涂层支架材料为介孔生物活性玻璃。
优选地，所述复合材料中钙磷支架材料或钙磷涂层支架材料为壳聚糖/纳米羟基磷灰石/煅烧骨(CH/TBC)。
本发明第三方面，提供上述缓释复合材料的制备方法，包括以下步骤：
S1：将所述可促进成骨并抑制破骨的活性多肽PTHrP-1或PTHrP-2的水溶液加入钙磷载体支架材料或钙磷涂层载体支架材料中；
S2：将所述含多肽载体支架材料－55℃冻干，即得到所述载促进成骨细胞并抑制破骨细胞活性的缓释复合材料。
优选地，S1中所述复合材料中材料大小为直径5mm、厚度2mm或直径4mm、长度15mm或长度20mm、宽度5mm、厚度2mm中的一种。
优选地，S1中所述复合材料中上述多肽PTHrP-1或PTHrP-2的含量为0.1-0.5mg。
本发明第四方面提供上述多肽PTHrP-1或PTHrP-2在制备促进成骨细胞并抑制破骨细胞活性药物中的应用。
优选地，该药物是多肽PTHrP-1或PTHrP-2搭载钙磷支架材料或钙磷涂层支架材料得到的复合材料。
优选地，该药物可以局部施用，而非只能全身给药。
在本发明的具体实施例中通过局部皮肤刺激试验、急性毒性试验、细胞毒性实验证实本发明提供的多肽安全性好。
在本发明的另一个具体实施例中将PTH相关多肽PTHrP-1或PTHrP-2和PTH1-34分别与介孔生物活性玻璃(MBG)复合，分为两组，MBG+1000ngPTH组和MBG+1000ngPTHrP-1或PTHrP-2组。分别将密度为1×105/ml的成骨细胞MC3T3-E1和破骨细胞RAW加入材料中共培养1d、3d、5d、7d。通过激光共聚焦显微镜或扫描电镜观察发现，PTH1-34组第一天由于PTH1-34的爆释，细胞生长旺盛，第3d和第5d成骨细胞出现凋亡，数量减少，第7d开始破骨细胞增多，以破骨细胞为主。PTHrP-1或PTHrP-2多肽组释放稳定，成骨细胞呈稳定趋势增长，第5d和第7d以成骨细胞为主，少有破骨细胞。证实PTHrP-1或PTHrP-2多肽具有促进成骨同时抑制破骨的作用。
在本发明的具体实施例中多肽PTHrP-1或PTHrP-2负载介孔生物活性玻璃(MBG)促进大鼠腰椎横突间融合和大鼠颅骨缺损的修复以及多肽PTHrP-1负载壳聚糖/纳米羟基磷灰石/煅烧骨(CH/TBC)支架材料修复兔桡骨缺损，证实多肽PTHrP-1或PTHrP-2搭载钙磷支架材料或钙磷涂层支架材料得到的复合材料可以局部施用。
本发明具有如下优点：
①所述多肽N端磷酸化丝氨酸可促进钙盐的沉积与矿化，骨诱导活性更佳。
②对PTH1-34进行优化修饰后，结构更加稳定，C端重复天冬氨酸或谷氨酸序列(3个D或3个E)能与钙磷材料表面的天然位点结合，从而可以在一定程度上避免多肽的无规卷曲，充分暴露多肽活性稳点，骨诱导活性更佳。
③所述多肽通过重复的天冬氨酸或谷氨酸序列(3个D或3个E)结合于钙磷支架材料上，不需要有机试剂的参入，可以有效地保护多肽的活性，并通过肽键的裂解实现达到间断缓慢控制释放。
④所述多肽与钙磷材料结合植入或与可注射含钙磷材料复合直接注射骨折端和骨缺损处，能在局部募集成骨细胞或促进向成骨细胞分化，同时通过调节剂量，可以最大限度的减少破骨细胞及骨质疏松的发生。避免了PTH1-34需全身给药和长期给药带来的风险和副作用。
⑤降解产物为氨基酸，不产生免疫反应和炎症反应。
⑥制备工艺简单，便于规模化生产。
附图说明
图1为PTHrP-1多肽(A)和PTHrP-2多肽(B)高效液相色谱法HPLC检测图；
图2为PTHrP-1多肽(A)和PTHrP-2多肽(B)质谱法MS检测图；
图3为MC3T3-E1细胞在PTHrP-1多肽诱导作用下生长正常，无毒性；
图4为不同浓度PTHrP-1多肽诱导MC3T3-E1细胞ALP染色图，图中100ng/ml组和200ng/ml组ALP阳性细胞明显多于50ng/ml组，100ng/ml组和200ng/ml组无明显差别；
图5为不同浓度PTHrP-1多肽诱导MC3T3-E1细胞ALP活性检测图，图中三种含PTHrP-1多肽的不同浓度的培养基中MC3T3-E1细胞的ALP活性随着成骨诱导时间的延长均持续增高，但100ng/ml组和200ng/ml组中MC3T3-E1细胞的ALP活性明显高于50ng/ml组，100ng/ml组和200ng/ml组无明显差别；
图6为不同浓度PTHrP-1多肽诱导MC3T3-E1细胞骨钙素OCN含量检测结果图，100ng/ml组和200ng/ml组中的OCN含量明显高于50ng/ml组和0ng/ml组，100ng/ml组和200ng/ml组无明显差别；
图7为PTHrP-1多肽负载介孔生物活性玻璃促进成骨细胞生长并抑制破骨细胞生长激光共聚焦图；
图8为PTHrP-2多肽负载介孔生物活性玻璃促进成骨细胞生长并抑制破骨细胞生长扫描电镜图；
图9为不同浓度PTHrP-1多肽负载介孔生物活性玻璃缓释曲线图；
图10为PTH相关多肽PTHrP-1负载介孔生物活性玻璃(MBG)修复SD大鼠腰椎横突间融合Micro CT检测图，图中0.5mg PTHrP-1/MBG复合支架组(A)骨修复效果明显优于0.1mgPTHrP-1/MBG复合支架组(B)，明显优于单纯支架组(C)；
图11为PTH相关多肽PTHrP-1负载介孔生物活性玻璃(MBG)修复SD大鼠腰椎横突间融合Van Gieson染色图，图中0.5mg PTHrP-1/MBG复合支架组(A)骨修复效果好于0.1mgPTHrP-1/MBG复合支架组(B)，明显好于单纯支架组(C)；
图12为PTH相关多肽PTHrP-2负载介孔生物活性玻璃(MBG)修复SD大鼠颅骨缺损Micro CT检测图，图中0.5mg PTHrP-2/MBG复合支架组(A1、A2)骨修复效果明显优于0.1mgPTHrP-2/MBG复合支架组(B1、B2)，明显优于单纯支架组(C1、C2)；
图13为PTH相关多肽PTHrP-2负载介孔生物活性玻璃(MBG)修复SD大鼠颅骨缺损Van Gieson染色图，图中0.5mg PTHrP-2/MBG复合支架组(A)骨修复效果好于0.1mg PTHrP-2/MBG复合支架组(B)，明显好于单纯支架组(C)；
图14为PTH相关多肽PTHrP-1负载壳聚糖/纳米羟基磷灰石/煅烧骨(CH/TBC)支架材料修复兔桡骨缺损第6周和第12周CT图，0.1mg PTHrP-1/CH/TBC复合支架组修复效果明显优于其它三组；
图15为PTH相关多肽PTHrP-1负载壳聚糖/纳米羟基磷灰石/煅烧骨(CH/TBC)支架材料修复兔桡骨缺损第6周和第12周HE染色图，0.1mg PTHrP-1/CH/TBC复合支架组修复效果明显优于其它三组。
具体实施方式
通过以下详细说明结合附图可以进一步理解本发明的特点和优点。所提供的实施例仅是对本发明方法的说明，而不以任何方式限制本发明揭示的其余内容。
发明人在实验过程中试验了以PTH1-34为主体进行剪切的多种多肽，结果发现多肽促进成骨细胞活性均不及PTH1-34。发明人尝试将N端丝氨酸磷酸化，同时在C端引入三个重复序列的谷氨酸(D)或天冬氨酸(E)，结果出乎意料地发现，所得多肽不仅能促进成骨细胞和抑制破骨细胞，而且能局部给药，与钙磷支架材料复合后，能有效地修复骨缺损及抑制骨质疏松。
【实施例1】多肽PTHrP-1和PTHrP-2的合成
实验中所需的多肽分子采用自动多肽合成仪合成，并通过高效液相色谱纯化，用质谱仪、氨基酸及多肽分析仪检测其纯度和序列。PTHrP-1和PTHrP-2的序列分别为 和 合成得到的纯度大于95％，分子量为4543.07Da，PTHrP-2分子量为4585.15Da。HPLC和MS如图1、图2所示。
【实施例2】多肽PTHrP-1毒性实验
1、局部皮肤刺激试验
取健康新西兰大白兔3只，雌雄不限，体重2.0-2.5kg，剪去背部兔毛，观察2d，皮肤无伤痕刺激，将浓度为100ng/mlPTHrP-1多肽溶液和生理盐水各0.2ml分别注射于脊柱两侧皮下，每侧取l0个点，注射后注射部位观察1d,3d,7d三个时间点。通过1d,3d,7d三个时间点观察，PTHrP-1多肽溶液和生理盐水注射部位均未见红肿，也未见红斑出现，提示PTHrP-1多肽对动物机体没有刺激性。
2、急性毒性试验
选健康小白鼠10只，体重20-25g，雌雄各半，分笼饲养。每只小白鼠腹腔内注射100ng/ml多肽溶液(50ml/kg)，注射后观察1d，3d，7d三个时间点，一周后处死小白鼠，组织学HE切片观察心、肝、脾、肺、肾等器官有无异常。所有小白鼠在试验期间均未出现毒性反应表现，进食正常，活动如常。各个时间点处死动物后各脏器大体观未见明显异常，各器官组织学HE染色切片未见异常。
3、细胞毒性实验
第3代小鼠MC3T3-E1细胞，密度为1×105/ml，加入6孔培养板中，每孔加入0.5ml细胞悬液，在37℃、体积分数为5％CO2培养箱中培养。将浓度为100ng/ml多肽溶液加入培养基中，每2-3d更换培养基。观察细胞生长情况，发现细胞生长正常，如图3所示。
【实施例3】多肽PTHrP-1促进MC3T3-E1细胞成骨分化最佳浓度
将四种含不同浓度的PTHrP-1多肽培养基(0ng/ml、50ng/ml、100ng/ml、200ng/ml)分别加入24孔培养板中，每种5孔。取第3代小鼠MC3T3-E1细胞，密度为1×105/ml，每孔加入0.5ml细胞悬液，在37℃、体积分数为5％CO2培养箱中培养，每2d更换培养基。培养14d，采用ALP试剂盒进行ALP染色。结果发现含PTHrP-1多肽三组培养孔中，MC3T3-E1细胞聚集，呈复层生长，细胞形态由圆形或类圆形逐渐变为多角形或立方形，细胞外基质分泌明显增多，ALP染色可见细胞胞浆中出现红棕色颗粒或棕褐色或咖啡色颗粒，是为ALP阳性细胞。其中100ng/ml组和200ng/ml组ALP阳性细胞明显多于50ng/ml组，100ng/ml组和200ng/ml组无明显差别，如图4所示。
同样方法，小鼠MC3T3-E1细胞培养5、10、15及20d，将24孔板中的细胞用PBS冲洗3次，用0.25％胰蛋白酶消化5～8min，每孔加入培养基1ml终止消化，4℃条件下10000rpm离心5min，再用PBS冲洗3次，加细胞裂解液破膜。按试剂盒说明进行ALP活性检测。通过紫外分光光度计在520nm波长处测定吸光度值(OD520)。ALP活性检测结果显示：三种含PTHrP-1多肽的不同浓度的培养基中MC3T3-E1细胞的ALP活性随着成骨诱导时间的延长均持续增高，但100ng/ml组和200ng/ml组中MC3T3-E1细胞的ALP活性明显高于50ng/ml组，100ng/ml组和200ng/ml组无明显差别，如图5所示。
同样方法，细胞诱导培养1、2、3及4w时，收集陈旧培养液及洗涤液，采用ELISA试剂盒检测培养液中OCN的含量。结果显示：100ng/ml组和200ng/ml组中的OCN含量明显高于50ng/ml组和0ng/ml组，100ng/ml组和200ng/ml组无明显差别，如图6所示。
ALP定性和定量实验以及OCN定量实验提示PTHrP-1多肽的体外诱导成骨最佳浓度为100ng/ml。
【实施例4】多肽PTHrP-1溶液与成骨细胞MC3T3-E1和破骨细胞RAW共培养
将多肽PTHrP-1和PTH1-34分别与介孔生物活性玻璃(MBG)复合，材料大小为10mm*10mm。分为两组，MBG+1000ngPTH组和MBG+1000ngPTHrP-1 组。分别将密度为1×105/ml的成骨细胞MC3T3-E1和破骨细胞RAW加入材料中共培养1d、3d、5d、7d。通过激光共聚焦显微镜观察发现，PTH1-34组第一天由于PTH1-34的爆释，细胞生长旺盛，第3d和第5d成骨细胞出现凋亡，数量减少，第7d开始破骨细胞增多，以破骨细胞为主。PTHrP-1多肽组释放稳定，成骨细胞呈稳定趋势增长，第5d和第7d以成骨细胞为主，少有破骨细胞。如图7所示，其中成骨细胞呈拉丝状，破骨细胞呈多核团状。证实PTHrP-1多肽具有促进成骨同时抑制破骨的作用。
【实施例5】多肽PTHrP-2溶液与成骨细胞MC3T3-E1和破骨细胞RAW共培养
将PTH相关多肽PTHrP-2和PTH1-34分别与介孔生物活性玻璃(MBG)复合，材料大小为10mm*10mm。分为两组，MBG+1000ngPTH组和MBG+1000ngPTHrP-2组。分别将密度为1×105/ml的成骨细胞MC3T3-E1和破骨细胞RAW加入材料中共培养1d、5d。分别将在两个时间点加入固定液固定细胞，通过扫描电镜观察成骨和破骨细胞共培养过程。结果发现，PTH1-34组第一天成骨细胞生长旺盛，第5d成骨细胞部分凋亡，数量减少，以破骨细胞为主。PTHrP-2多肽组成骨细胞呈稳定趋势增长，第5d仍以成骨细胞为主，少有破骨细胞。如图8所示，其中成骨细胞呈拉丝状，破骨细胞呈多核团状。证实PTHrP-2多肽具有促进成骨同时抑制破骨的作用。
【实施例6】多肽PTHrP-1负载介孔生物活性玻璃(MBG)的缓释性
将制备好的0.1mg PTHrP-1/MBG材料和0.5mg PTHrP-1/MBG材料分别浸入5ml配制好的PBS溶液中，在37℃条件下浸泡7d。在分别浸泡2h，6h,12h,24h,2d,3d,4d,5d,6d和7d后，检测洗出液中PTHrP-1多肽的量。在每个时间间隔中，洗出液均被完全移除，然后重新倒入PBS溶液。所收集的洗出液中PTHrP-1多肽的量用PTH ELISA试剂盒进行检测。如图9所示，不同浓度的PTHrP-1/MBG材料均具有缓慢释放的特性。
【实施例7】多肽PTHrP-1负载介孔生物活性玻璃(MBG)促进大鼠腰椎横突间融合(骨修复)
将18只健康雄性SD大鼠随机分为3组，每组10只，其中A组植入0.5mgPTHrP-1/MBG材料，B组植入0.1mg PTHrP-1/MBG材料，C组植入单纯MBG材料。10％水合氯醛腹腔注射麻醉，沿腰椎棘突作后中线切口，然后在距中线4mm 处做两个单独的筋膜切口。钝性分离，显露L4和L5横突，充分暴露后，用庆大霉素/生理盐水溶液冲洗融合床，并使用高速钻头去除横突皮质骨，然后在L4-L5横突处分别植入三组材料，缝合伤口。术后12周行放射学和组织学检测。如图10、图11所示，PTH相关多肽PTHrP-1负载介孔生物活性玻璃(MBG)能明显促进大鼠腰椎横突间融合。
【实施例8】多肽PTHrP-2负载介孔生物活性玻璃(MBG)促进大鼠颅骨缺损的修复
将30只健康雄性SD大鼠随机分为3组，每组10只，其中A组植入0.5mg PTHrP-2/MBG材料，B组植入0.1mg PTHrP-2/MBG材料，C组植入单纯MBG材料。10％水合氯醛腹腔注射麻醉，取颅顶正中纵行切口，于颅骨正中缝和人字缝交叉的外下象限空白处两侧，分别作一直径为5mm的圆形骨缺损区，分别同时植入上述三组材料，缝合。分别于术后6周和12周每组各分别处死4只和6只大鼠，取颅骨做放射学和组织学检测。如图12、图13所示，PTH相关多肽PTHrP-2负载介孔生物活性玻璃(MBG)能明显促进大鼠颅骨缺损的修复。
【实施例9】多肽PTHrP-1负载壳聚糖/纳米羟基磷灰石/煅烧骨(CH/TBC)支架材料修复兔桡骨缺损
取4-6月龄新西兰大白兔48只，雄性，体重2.0-2.5kg，每只大白兔术前均用戊巴比妥钠(25mg/kg)和甲苯噻嗪(8mg/kg)肌肉注射麻醉。麻醉满意后，用弯剪剔除左前肢兔毛，然后用1％活力碘消毒灭菌。常规铺巾。以尺桡骨中点为中心作纵行切口，长约18mm，逐层切开皮肤、筋膜及肌层，显露左侧尺桡骨中段。用自制小刀锯造15mm长度桡骨中段缺损。分别将四组材料植入缺损处(空白组、CH/TBC组、0.01mgPTHrP-1/CH/TBC组、0.1mgPTHrP-1/CH/TBC组)。术后6周和12周行放射学和组织学检查。如图14、图15所示，0.1mgPTHrP-1负载壳聚糖/纳米羟基磷灰石/煅烧骨(CH/TBC)支架材料能明显促进兔桡骨缺损修复。
以上所述仅为本发明的较佳实施例，并不用以限制本发明，凡在本发明的精神和原则之内，所作的任何修改、等同替换、改进等，均应包含在本发明的保护范围之内。
序列表
<110> 武汉大学
<120> 一种可促进成骨并抑制破骨的活性多肽及其应用
<160> 2
<170> SIPOSequenceListing 1.0
<210> 1
<211> 37
<212> PRT
<213> 人工序列(Artificial Sequence)
<220>
<221> PHOSPHORYLATION
<222> (1)..(1)
<400> 1
Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu Asn
1 5 10 15
Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
20 25 30
Asn Phe Asp Asp Asp
35
<210> 2
<211> 37
<212> PRT
<213> 人工序列(Artificial Sequence)
<220>
<221> PHOSPHORYLATION
<222> (1)..(1)
<400> 2
Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu Asn
1 5 10 15
Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
20 25 30
Asn Phe Glu Glu Glu
35
Claims (8)
1.一种可促进成骨并抑制破骨的活性多肽，其特征在于，该多肽是在PTH1-34的基础上将N端丝氨酸磷酸化，同时在C端引入三个重复序列的谷氨酸（D）或天冬氨酸（E），其氨基酸序列如SEQ ID NO:1或SEQ ID NO:2所示。
2.一种缓释复合材料，其特征在于，由权利要求1所述的可促进成骨细胞活性并抑制破骨细胞活性的多肽搭载钙磷支架材料或钙磷涂层支架材料得到。
3.根据权利要求2所述的缓释复合材料，其特征在于，所述的钙磷支架材料或钙磷涂层支架材料为介孔生物活性玻璃。
4.根据权利要求2所述的缓释复合材料，其特征在于，所述的钙磷支架材料或钙磷涂层支架材料为壳聚糖/纳米羟基磷灰石/煅烧骨。
5.权利要求2-4任一项所述的缓释复合材料的制备方法，其特征在于，包括以下步骤：
S1：将权利要求1所述的可促进成骨并抑制破骨的活性多肽的水溶液加入钙磷载体支架材料或钙磷涂层载体支架材料中，；
S2：将S1获得的含多肽载体支架材料－55℃冻干，即得到载促进成骨细胞并抑制破骨细胞活性的多肽的缓释复合材料。
6.根据权利要求5所述的缓释复合材料的制备方法，其特征在于，S1中所述钙磷载体支架材料或钙磷涂层载体支架材料大小为直径5mm、厚度2mm或直径4mm、长度15mm或长度20mm，宽度5mm，厚度2mm中的一种。
7.根据权利要求5或6所述的缓释复合材料的制备方法，其特征在于，S1中所述促进成骨并抑制破骨的活性多肽的含量为0.1 -0.5mg。
8.权利要求1所述的多肽或权利要求2-4任一项所述的缓释复合材料在制备促进成骨并抑制破骨的活性药物中的应用，其特征在于，所述药物是局部施用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711459182.9A CN108276487B (zh) | 2017-12-28 | 2017-12-28 | 一种可促进成骨并抑制破骨的活性多肽及其应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711459182.9A CN108276487B (zh) | 2017-12-28 | 2017-12-28 | 一种可促进成骨并抑制破骨的活性多肽及其应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108276487A true CN108276487A (zh) | 2018-07-13 |
| CN108276487B CN108276487B (zh) | 2020-11-17 |
Family
ID=62802555
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711459182.9A Active CN108276487B (zh) | 2017-12-28 | 2017-12-28 | 一种可促进成骨并抑制破骨的活性多肽及其应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108276487B (zh) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110433337A (zh) * | 2019-05-09 | 2019-11-12 | 西南交通大学 | 双向调控成骨与破骨细胞响应行为涂层及其构建方法 |
| WO2020087555A1 (zh) * | 2018-10-31 | 2020-05-07 | 杨德鸿 | 一种基于蛋白结构域重建的新型pth模拟肽及其应用 |
| CN112957451A (zh) * | 2021-02-26 | 2021-06-15 | 四川大学 | 生物活性玻璃/仿生功能多肽复合体及制备方法和应用 |
| CN114853852A (zh) * | 2022-05-25 | 2022-08-05 | 四川大学 | 多肽及其在促进骨修复中的用途 |
| CN114957404A (zh) * | 2022-05-17 | 2022-08-30 | 四川大学 | 一种多肽及其在促进骨修复中的用途 |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005072770A1 (en) * | 2004-01-26 | 2005-08-11 | Ferring B.V. | Treatment of bone metastases by means of pth receptor agonists |
| CN1752103A (zh) * | 2005-10-27 | 2006-03-29 | 华中科技大学同济医学院附属协和医院 | 骨形态发生蛋白2活性肽及制备方法和应用 |
| US20060069021A1 (en) * | 2004-08-13 | 2006-03-30 | Nastech Pharmaceutical Company Inc. | Compositions and methods for intranasal administration of inactive analogs of PTH or inactivated preparations of PTH or PTH analogs |
| WO2006039258A2 (en) * | 2004-09-30 | 2006-04-13 | Abgenix, Inc. | Human antibodies against parathyroid hormone |
| CN101098717A (zh) * | 2005-01-06 | 2008-01-02 | 库罗斯生物外科股份公司 | 用于修复骨折的补充的基质 |
| US20110311643A1 (en) * | 2005-01-06 | 2011-12-22 | Kuros Biosurgery Ag | Supplemented matrices for the repair of bone fractures |
| CN102886075A (zh) * | 2012-09-19 | 2013-01-23 | 中南大学 | 人体硬组织修复材料及其制备方法 |
-
2017
- 2017-12-28 CN CN201711459182.9A patent/CN108276487B/zh active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005072770A1 (en) * | 2004-01-26 | 2005-08-11 | Ferring B.V. | Treatment of bone metastases by means of pth receptor agonists |
| US20060069021A1 (en) * | 2004-08-13 | 2006-03-30 | Nastech Pharmaceutical Company Inc. | Compositions and methods for intranasal administration of inactive analogs of PTH or inactivated preparations of PTH or PTH analogs |
| WO2006039258A2 (en) * | 2004-09-30 | 2006-04-13 | Abgenix, Inc. | Human antibodies against parathyroid hormone |
| CN101098717A (zh) * | 2005-01-06 | 2008-01-02 | 库罗斯生物外科股份公司 | 用于修复骨折的补充的基质 |
| US20110311643A1 (en) * | 2005-01-06 | 2011-12-22 | Kuros Biosurgery Ag | Supplemented matrices for the repair of bone fractures |
| CN1752103A (zh) * | 2005-10-27 | 2006-03-29 | 华中科技大学同济医学院附属协和医院 | 骨形态发生蛋白2活性肽及制备方法和应用 |
| CN102886075A (zh) * | 2012-09-19 | 2013-01-23 | 中南大学 | 人体硬组织修复材料及其制备方法 |
Non-Patent Citations (11)
| Title |
|---|
| DOSE-DEPENDENCE OF PTH-RELATED PEPTIDE-1 ON THE OSTEOGENIC INDUC: "Dose-dependence of PTH-related peptide-1 on the osteogenic induction of MC3T3-E1 cells in vitro", 《MEDICINE》 * |
| QUAN ZHANG等: "Long-term controlled release of 125I-tagged BMP-2 by mesoporous bioactive glass with ordered nanopores", 《EXPERIMENTAL AND THERAPEUTIC MEDICINE》 * |
| SHOHEI KASUGAI等: "Selective Drug Delivery System to Bone: Small Peptide (Asp)6 Conjugation", 《JOURNAL OF BONE AND MINERAL RESEARCH》 * |
| XIAOHUA YU等: "Biomimetic CaP coating incorporated with parathyroid hormone improves the osseointegration of titanium implant", 《JOURNAL OF MATERIALS SCIENCE: MATERIALS IN MEDICINE》 * |
| 余家会等: "《纳米生物医药》", 31 December 2011, 华东理工大学出版社 * |
| 吴梧桐等: "《生物化学》", 31 August 2015, 中国医药科技出版社 * |
| 孙智慧等: "局部应用重组人甲状旁腺激素(1-34)对即刻种植骨整合的作用", 《中国组织工程研究》 * |
| 杨大志等: "多肽对生物材料表面修饰的研究现状", 《国外医学生物医学工程分册》 * |
| 王成焘: "《骨科植入物工程学 上册》", 31 October 2016, 上海交通大学出版社 * |
| 窦筠等: "《生物陶瓷》", 28 February 1992, 化学工业出版社 * |
| 章晔: "新型有序纳米介孔生物活性玻璃作为骨组织工程支架材料的基础性研究", 《中国博士学位论文全文数据库医药卫生科技辑》 * |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020087555A1 (zh) * | 2018-10-31 | 2020-05-07 | 杨德鸿 | 一种基于蛋白结构域重建的新型pth模拟肽及其应用 |
| US11912752B2 (en) | 2018-10-31 | 2024-02-27 | Dehong YANG | PTH mimetic peptide based on protein domain reconstruction and application thereof |
| CN110433337A (zh) * | 2019-05-09 | 2019-11-12 | 西南交通大学 | 双向调控成骨与破骨细胞响应行为涂层及其构建方法 |
| CN110433337B (zh) * | 2019-05-09 | 2021-02-02 | 西南交通大学 | 双向调控成骨与破骨细胞响应行为涂层及其构建方法 |
| CN112957451A (zh) * | 2021-02-26 | 2021-06-15 | 四川大学 | 生物活性玻璃/仿生功能多肽复合体及制备方法和应用 |
| CN112957451B (zh) * | 2021-02-26 | 2021-12-17 | 四川大学 | 生物活性玻璃/仿生功能多肽复合体及制备方法和应用 |
| CN114957404A (zh) * | 2022-05-17 | 2022-08-30 | 四川大学 | 一种多肽及其在促进骨修复中的用途 |
| CN114957404B (zh) * | 2022-05-17 | 2023-04-25 | 四川大学 | 一种多肽及其在促进骨修复中的用途 |
| CN114853852A (zh) * | 2022-05-25 | 2022-08-05 | 四川大学 | 多肽及其在促进骨修复中的用途 |
| CN114853852B (zh) * | 2022-05-25 | 2023-04-25 | 四川大学 | 多肽及其在促进骨修复中的用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108276487B (zh) | 2020-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108276487A (zh) | 一种可促进成骨并抑制破骨的活性多肽及其应用 | |
| Beniash et al. | The effect of recombinant mouse amelogenins on the formation and organization of hydroxyapatite crystals in vitro | |
| DE69034040T2 (de) | Rekombinanter Abkömmling des menschlichen Faktors VIII | |
| DE3851776T2 (de) | Verwendung von IGF-II zur Behandlung von Knochenkrankheiten. | |
| CN102573884B (zh) | 从蜘蛛毒液中分离的新型肽及其应用 | |
| DE69635675T2 (de) | Verkürzter aus einer gliazelllinie gewonnener neurotropher faktor | |
| EA011586B1 (ru) | Новый карбамилированный еро и способ его получения | |
| JPH05506030A (ja) | 哺乳動物に組織修復促進の傾向を与える方法 | |
| JP2012235784A (ja) | 骨形成タンパク質の変異タンパク質及びその使用 | |
| JP2009502782A (ja) | 硬組織形成を促進するためのタンパク質製剤 | |
| DE69333745T2 (de) | Löslicher komplex morphogener proteine und zusammensetzungen davon | |
| EP1313440B1 (en) | Dental products comprising bone growth enhancing peptide | |
| US9694047B2 (en) | Enhancement of bone morphogenic protein (BMP) retention with BMP binding peptide (BBP) | |
| EP0625163B1 (de) | Parathormonfragmente, deren herstellung und diese enthaltende arzneimittel | |
| DE69426209T2 (de) | Stannius- körperchen -protein, stanniocalcin | |
| DE69933057T2 (de) | Analoge des humanen basischen fibroblasten-wachstumsfactors | |
| DE69029415T2 (de) | Osteogenische Wachstumfaktoren, die aus sich regenerierendem Knochenmark identifiziert werden | |
| CN102068688A (zh) | 力生长因子及其e肽在制备治疗骨质疏松或骨缺损的药物及材料中的应用 | |
| CN109715656A (zh) | 用于诱导组织形成的化合物及其用途 | |
| EP1805215A2 (de) | Chemisch modifizierte iapp-peptidanaloga | |
| CN1323167C (zh) | 1型胎盘生长因子的突变蛋白及其制备方法和应用 | |
| JP3135138B2 (ja) | 骨疾患治療剤 | |
| EP1023445B1 (de) | Cadherin derived growth factor und seine verwendung | |
| EP1267916B1 (de) | Arzneimittel enthaltend tissue inhibitor of metalloproteinases-2 (timp-2) als osteoanabol wirksame substanz | |
| JP2011527673A (ja) | 骨再生用コラーゲンゲル組成物の調製方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |